DOI: 10.3390/microorganisms7020042; PMCID: PMC6406338
Infection with nontuberculous mycobacteria (NTM) is a complication of lung disease in immunocompromised patients, including those with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The most widespread, disease-causing NTM is Mycobacterium avium complex (MAC), which colonizes the lungs as a combination of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacterial species. While combination drug therapy exists for MAC colonization, there is no cure. Therapeutic development to treat MAC has been difficult because of the slow-growing nature of the bacterial complex, limiting the ability to characterize the bacteria's growth in response to new therapeutics. The development of a technology that allows observation of both the MAC predominant strains and MAC could provide a means to develop new therapeutics to treat NTM. We have developed a new methodology in which M. avium and M. intracellulare can be optimally grown in short term culture to study each strain independently and in combination, as a monitor of growth kinetics and efficient therapeutic testing protocols.
Mycobacterium avium; Mycobacterium intracellulare; anti-non-tuberculous mycobacterium therapeutic testing; optimized growth
Auster L, Sutton M, Gwin MC, Nitkin C, Bonfield TL. Optimization of In Vitro Mycobacterium avium and Mycobacteriumintracellulare Growth Assays for Therapeutic Development. Microorganisms. 2019;7(2):42. Published 2019 Feb 1. doi:10.3390/microorganisms7020042